News
ACOG
5.95
+8.38%
0.46
Craig-Hallum Sticks to Its Buy Rating for Alpha Cognition Inc (ACOG)
TipRanks · 1d ago
Weekly Report: what happened at ACOG last week (0504-0508)?
Weekly Report · 3d ago
Weekly Report: what happened at ACOG last week (0427-0501)?
Weekly Report · 05/04 10:24
Alpha Cognition amends 8-K, names Bethany Sensenig audit committee chair
PUBT · 05/01 20:41
Alpha Cognition to report quarterly results, host conference call after market close
PUBT · 04/28 20:55
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
Barchart · 04/28 15:30
Alpha Cognition CEO to join H.C. Wainwright BioConnect investor conference
PUBT · 04/27 12:05
Alpha Cognition Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 04/27 11:23
HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target
Benzinga · 04/27 11:13
Weekly Report: what happened at ACOG last week (0420-0424)?
Weekly Report · 04/27 10:27
Alpha Cognition: Buy Rating Reaffirmed as Early Galantos Settlement Enhances Financial Flexibility; $18 Price Target Maintained
TipRanks · 04/27 10:25
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Barchart · 04/27 07:00
Alpha Cognition appoints Bethany Sensenig to board of directors
PUBT · 04/20 21:00
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
Barchart · 04/20 16:00
Weekly Report: what happened at ACOG last week (0413-0417)?
Weekly Report · 04/20 10:23
Craig-Hallum Initiates Coverage of Alpha Cognition (ACOG) with Buy Recommendation
NASDAQ · 04/18 00:04
Emmaus Life Sciences appoints Henry H. Du to board after Kuwahara resignation
PUBT · 04/17 21:17
Alpha Cognition files Form 3 as director Bethany Sensenig reports no holdings
PUBT · 04/17 19:56
Alpha Cognition Price Target Announced at $14.00/Share by Craig-Hallum
Dow Jones · 04/17 13:30
Craig-Hallum Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $14
Benzinga · 04/17 13:20
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.